-
CIFTIS Opens International Consumption Day of Traditional Chinese Medicine to Explore Inheritance, Innovation and Development
Time of Update: 2022-09-07
The Beijing Municipal Administration of Traditional Chinese Medicine and the Beijing Intellectual Property Office jointly released the Action Plan for Strengthening the Foundation of Intellectual Property Rights of Traditional Chinese Medicine in Beijing, which will help consolidate the foundation of Beijing's traditional Chinese medicine intellectual property work, stimulate the innovation and creativity of the medical and health industry, and protect and stimulate scientific research.
-
What is the difference between a beautiful pupil and contact lenses? Will it fade? Is wearing it harmful to the eyes for a long time?
Time of Update: 2022-09-07
Chen Zhanbiao, director of the Department of Ophthalmology of Fuzhou First Hospital: This (case) is also after wearing a beautiful pupil, there is red eye pain, fear of light and tears, foreign body sensation, and decreased vision.
-
From October 20, 279 proprietary Chinese medicines in Hunan Province will reduce prices! There are varieties down to less than 1 yuan
Time of Update: 2022-09-07
In addition to the amount of procurement agreed, medical institutions may purchase unselected drugs with appropriate prices according to clinical needs, and the purchase amount of all drugs (including selected drugs and non-selected drugs) in the collection catalogue of proprietary Chinese medicines shall not exceed 85% of the same period of the previous year.
-
25 pharmaceutical and biological companies were surveyed by more than 20 institutions!
Time of Update: 2022-09-07
Among them, the net profit attributable to the parent company of two companies in the first half of the year increased by more than 50% year-on-year, namely Adopt Shares and Xiangsheng Medical.
-
In 2022, the performance of H1 head pharmaceutical machine companies is bright, and the agency expects that the annual net profit will continue to grow
Time of Update: 2022-09-07
The agency expects that the annual net profit of the head will continue to grow Since the second half of the year, institutions have made predictions on the 2022 annual performance of listed pharmaceutical machine companies.
-
Shanhe Pharmaceutical Co., Ltd. "A preparation method of low-pine density cross-linked carboxymethyl cellulose sodium" won the national invention patent authorization
Time of Update: 2022-09-07
Shanhe Pharmaceutical Auxiliary implements the development strategy of rejuvenating enterprises with science and technology, and adheres to scientific and technological innovation and independent research and development for a long time.
-
Announcement on the time of the "88th API China & 26th CHINA-PHARM"
Time of Update: 2022-09-07
The second China Pharmaceutical CXO Conference and nearly 30 wonderful conferences will be held at the same time of the exhibition, and we look forward to meeting you again!Dear exhibitors, visitors and friends in the industry: In view of the recent spread and frequent outbreak of the new crown pneumonia epidemic, the situation is complex and changeable.
-
Policy interpretation of the Measures for the Supervision and Administration of Drug Network Sales
Time of Update: 2022-09-07
I. What is the background of the formulation of the Measures for the Supervision and Administration of Drug Network Sales (hereinafter referred to as the Measures)? In recent years, with the rapid de
-
After the epidemic, the leader may quickly change hands, will Merck have a chance to compete?
Time of Update: 2022-09-07
The new crown epidemic is a thing of the past, and sales are rising and falling As Lei Jun once said: "Standing on the wind outlet, pigs can fly", not to mention the multinational pharmaceutical companies that are already strong in strength, standing on the right outlet, the advantage is naturally facing wireless expansion.
-
Focus on the medical reform in Huzhou, Zhejiang: realize that the grass-roots people have "medical" reliability
Time of Update: 2022-09-07
Municipal public hospitals achieve full coverage of "top three", and 80% of municipal hospitals have reached the level of A and above in the national examination; "Healthy City Model City" is the third in the country and the first in Zhejiang; Medical reform was selected into the list of best practices for the first batch of high-quality development and construction of common prosperity demonstration zones in Zhejiang Province, and was the first in Zhejiang's assessment for 4 consecutive years.
-
Affected by rising costs, a large number of pharmaceutical companies will go bankrupt and go bankrupt!
Time of Update: 2022-09-07
In fact, looking at the entire pharmaceutical industry, not only overseas pharmaceutical companies, but also domestic pharmaceutical companies are generally under pressure due to factors such as rising costs, centralized procurement, medical insurance cost control, and fierce market competition, and gradually go bankrupt, closed down .
-
10% opposition to oral price governance? Who is blocking the price reduction of dental implants?
Time of Update: 2022-09-07
On September 2, the National Medical Insurance Bureau issued the notice on the public solicitation of comments on the previous "Notice on Carrying out Special Governance of Oral Implant Medical Servi
-
Interpretation of the paediatric drug market pattern, track overtaking focuses on subdivisions
Time of Update: 2022-09-07
The underlying logic of the opportunities in the pediatric drug market lies in the huge Chinese market, the increasingly wealthy citizens' attention to children's health, the government's continuous attention and investment in this field, and the advantages of the national system .
-
It is expected to reach a market of 28.8 billion yuan! Domestic pharmaceutical companies actively lay out the CAR-T therapy track
Time of Update: 2022-09-07
In addition to the expansion of more indications, Fosun Kate's second CAR-T cell therapy product, FKC889, for the treatment of adult patients with relapsed/refractory sleeve cell lymphoma (r/r MCL) after second-line or above treatment, was approved for clinical trials in China in March 2022.
-
The collection of proprietary Chinese medicines covers most of the provinces, and the pressure of price reduction is unprecedented!
Time of Update: 2022-09-07
On the other hand, the winning products in the collection also face competition from proprietary Chinese medicines that have not entered the collection of the same indications, the latter has not reduced prices, and there is more profit space for market promotion and competition for the former market.
-
The imported nine-valent HPV vaccine is suitable for the expansion of the domestic population. Can the four-valent HPV vaccine be used again?
Time of Update: 2022-09-07
(Finish)Severe allergic reactions to any of the active ingredients or excipients On the 30th, the "Merck China" WeChat account announced that the new indication of its nine-valent human papillomavirus vaccine (nine-valent HPV vaccine) has been approved by the National Medical Products Administration of China.
-
62 varieties have been evaluated, and 12 varieties have been evaluated for the first time! Hainan General Sanyo, Yangtze River, Huahai...
Time of Update: 2022-09-07
Figure 6 Top 2022 in august 8 for the number of enterprise declaration acceptance numbers Data source: Yaozhi data, Yaozhi consulting collation Hainan General Sanyo Pharmaceutical Co.
-
The production of medicinal herbs has been reduced to a sharp increase in prices! Chinese medicine raw materials are facing many tests
Time of Update: 2022-09-07
Ups and downs It has the greatest impact on rhizomes, fruit seeds and animals From the perspective of rising and falling varieties, the provinces with a high proportion of rising varieties of raw materials are mainly concentrated at the end of the irrigation areas of the Yangtze River Basin.
-
In the first half of 2022, the total disclosed transaction volume of China's medical and health service industry is 25.4 billion yuan
Time of Update: 2022-09-07
The report "Trends of M&A Transactions in the Healthcare Industry in the First Half of 2022" released by PricewaterhouseCoopers on the 4th at the 2022 Service Trade Fair pointed out that the repeated epidemics in many places in the first half of the year affected the development of investment and financing M&A activities to a certain extent, and the capital market was active.
-
Consistency evaluation of generic drugs is advancing!
Time of Update: 2022-09-06
On July 29, information from the State Food and Drug Administration showed that Huahai Pharmaceutical's 4 types of generic valsartan and hydrochlorothiazide tablets for the treatment of mild to moderate essential hypertension whose blood pressure cannot be adequately controlled by a single drug was approved .
